智通财经APP获悉，花旗发布研报称，给予巨子生物(02367)“买入”评级，基于2025年预测市盈率约25倍，将目标价由61港元上调至68.2港元。该行称巨子生物是消费者对产品科学性的重视日益增长以及对肌肤修护需求不断上升的主要受益者。
据悉，巨子生物近日推出了一个新的产品系列“帧域密修”，该系列以其新的专利重组胶原蛋白成分，针对热损伤后的肌肤护理，尤其是光电治疗后的护理，令公司的修护产品线从基础和一般修护，拓展到更专业及精准护理领域，有助带来新收入来源、巩固其以科学为导向的产品定位，并建立了专业品牌形象。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.